Skip to main content

Table 4 Characteristics of the included studies in the meta-analysis

From: E-cadherin expression phenotypes associated with molecular subtypes in invasive non-lobular breast cancer: evidence from a retrospective study and meta-analysis

Studies Country Recruited period No. of patients % of ILC/IDC Stage of disease Tissue processing Antibody/Cutoff % of E-cad expression Molecular subtypes
Non-TNBC TNBC
Aleskandarany et al. [27] UK 1990–1998 1035 0/70% NR TMA C3865/>100 H-scorea 50% (519/1035) 808 (luminal 652, HER2-enriched 156) 197
Choi et al. [11] Korea 2009–2011 382 of 438 0/91% (397/438) I–IV TMA NCH-38/10% 65% (247/382) 313 (luminal A 177, luminal B 96, HER2-enriched 40) 69
Jeong et al. [17] Korea 1992–2006 492 0.6/97% I–IV TMA SPM471/NR 85% (418/492) 363 (luminal 221, HER2-enriched 142) 102
Kashiwagi et al. [16] Japan 2000–2006 574 0/83% I–III Whole slide section NCH-38/≥30% 59% (336/574) 451 123
Liu et al. [25] China 2000–2004 441 NR I–IV Whole slide section Abcam/>10% 63% (276/441) 264 (luminal A 84, luminal B 90, HER2-enriched 90) 177
Mahler-Araujo et al. [12] UK NR 180 of 245 0/87% (156/180) NR TMA HECD-1/≥50% 65% (142/217) 154 26
Pang et al. [26] China 2001–2002 170 9%/78% I–III Whole slide section Santa/>10% 36% (61/170) 129 41
Pomp et al. [28] Switzerland 1991–2011 617 15%(87/565)/80% (454/565) I–IV TMA EP700Y/>50% 88% (527/598) 478 (luminal 439, HER2-enriched 39) 120
Rakha et al. [22] UK 1986–1998 1711 of 1722 NR/80% (1378/1722) I–IV TMA HECD-1/>100 H-score 46% (795/1711) 1436 275
Sarrio et al. [23] Spain 1993–2001 491 5/93% NR TMA 4A2C7/≥50% 45% (221/491) 399 64
Wu et al. [24] China 2000–2006 382 2%/93% I–IV Whole slide section 4A2C7/≥50% 79% (301/382) 341 (luminal A 232, luminal B 45, HER2-enriched 64) 41
This study China 2011–2014 156 0/100% I–II Whole slide section 4A2C7/≥50% 83% (129/156) 118 (luminal A 30, luminal B 74, HER2-enriched 14) 38
  1. ILC invasive lobular carcinoma, IDC invasive ductal carcinoma of the breast, TNBC triple-negative breast cancer, NR not reported, TMA tissue microarray
  2. aA semi-quantitative histochemical score method taking into account the intensity of staining and percentage of stained cells and giving a continuous measure (0–300) of marker expression [27]